- Home
- NVT vs MEDP Comparison
NVT vs MEDP Comparison
Compare NVT & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVT
- MEDP
- Stock Information
- Founded
- NVT 1903
- MEDP 1992
- Country
- NVT United Kingdom
- MEDP United States
- Employees
- NVT N/A
- MEDP N/A
- Industry
- NVT Industrial Machinery/Components
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- Sector
- NVT Industrials
- MEDP Health Care
- Exchange
- NVT Nasdaq
- MEDP Nasdaq
- Market Cap
- NVT 11.1B
- MEDP 10.5B
- IPO Year
- NVT N/A
- MEDP 2016
- Fundamental
- Price
- NVT $52.91
- MEDP $312.74
- Analyst Decision
- NVT Strong Buy
- MEDP Buy
- Analyst Count
- NVT 8
- MEDP 10
- Target Price
- NVT $80.13
- MEDP $373.22
- AVG Volume (30 Days)
- NVT 2.5M
- MEDP 384.3K
- Earning Date
- NVT 05-02-2025
- MEDP 04-21-2025
- Dividend Yield
- NVT 1.51%
- MEDP N/A
- EPS Growth
- NVT N/A
- MEDP 42.23
- EPS
- NVT 1.97
- MEDP 12.63
- Revenue
- NVT $3,006,100,000.00
- MEDP $2,109,054,000.00
- Revenue This Year
- NVT $9.28
- MEDP $4.64
- Revenue Next Year
- NVT $5.45
- MEDP $9.74
- P/E Ratio
- NVT $37.00
- MEDP $24.73
- Revenue Growth
- NVT 12.63
- MEDP 11.84
- 52 Week Low
- NVT $51.99
- MEDP $302.01
- 52 Week High
- NVT $86.57
- MEDP $459.77
- Technical
- Relative Strength Index (RSI)
- NVT 33.62
- MEDP 40.74
- Support Level
- NVT $55.55
- MEDP $314.00
- Resistance Level
- NVT $59.45
- MEDP $331.24
- Average True Range (ATR)
- NVT 1.82
- MEDP 8.84
- MACD
- NVT 0.20
- MEDP -0.39
- Stochastic Oscillator
- NVT 8.91
- MEDP 18.32
About NVT nVent Electric plc
nVent is a leading global provider of electrical connection and protection solutions that touches a broad range of end markets including infrastructure, industrial, commercial, and residential. NVent designs, manufacturers, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.